Literature DB >> 11372749

Secondary chronic myelogenous leukemia after autologous peripheral blood stem cell transplantation for lymphoma.

H H Hsiao1, T C Liu, C S Chang, Y C Sue, T P Chen, S F Lin.   

Abstract

A 31-year-old woman was diagnosed with intestinal lymphoma (high-grade mucosa-associated lymphoid tissue lymphoma, stage IIE) in September 1996. Eleven courses of chemotherapy were administered, but the results were poor. She received autologous peripheral blood stem cell transplantation (PBSCT) in September 1997. Leukocytosis was noted, and chronic myelogenous leukemia was diagnosed 8 months after the PBSCT, progressing to blast phase 10 months later. We report this case because secondary chronic myelogenous leukemia after stem cell transplantation is rare.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11372749     DOI： 10.1007/bf02981915

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


  13 in total

Review 1.  Risk of secondary myeloid leukemia and myelodysplastic syndrome following standard-dose chemotherapy or high-dose chemotherapy with stem cell support in patients with potentially curable malignancies.

Authors:  C Kollmannsberger; J T Hartmann; L Kanz; C Bokemeyer
Journal:  J Cancer Res Clin Oncol       Date:  1998       Impact factor: 4.553

2.  Chronologic sequence in appearance of clinical and laboratory findings characteristic of chronic myelocytic leukemia.

Authors:  N Kamada; H Uchino
Journal:  Blood       Date:  1978-05       Impact factor: 22.113

3.  Secondary chronic myelogenous leukemia after chemotherapy followed by adjuvant radiotherapy for small cell lung cancer.

Authors:  C F Waller; S Fetscher; W Lange
Journal:  Leuk Res       Date:  1999-10       Impact factor: 3.156

4.  Rapid onset of chronic granulocytic leukaemia after treatment for Hodgkin's disease.

Authors:  G H Jackson; J A Latham; A L Lennard; P R Taylor; S J Proctor
Journal:  Br J Haematol       Date:  1994-05       Impact factor: 6.998

5.  Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study.

Authors:  R E Curtis; L B Travis; P A Rowlings; G Socié; D W Kingma; P M Banks; E S Jaffe; G E Sale; M M Horowitz; R P Witherspoon; D A Shriner; D J Weisdorf; H J Kolb; K M Sullivan; K A Sobocinski; R P Gale; R N Hoover; J F Fraumeni; H J Deeg
Journal:  Blood       Date:  1999-10-01       Impact factor: 22.113

6.  Duration of the preclinical phase of chronic myelogenous leukemia: a case report.

Authors:  E Berman; A Strife; D Wisniewski; S Desai; S Gulati; S Jhanwar; B D Clarkson
Journal:  Blood       Date:  1991-12-01       Impact factor: 22.113

7.  Secondary malignancies after bone marrow transplantation in adults.

Authors:  R Lowsky; J Lipton; G Fyles; M Minden; J Meharchand; I Tejpar; H Atkins; S Sutcliffe; H Messner
Journal:  J Clin Oncol       Date:  1994-10       Impact factor: 44.544

8.  Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals.

Authors:  C Biernaux; M Loos; A Sels; G Huez; P Stryckmans
Journal:  Blood       Date:  1995-10-15       Impact factor: 22.113

9.  Long-term survivors: an overview on late effects, sequelae and second neoplasias.

Authors:  D Niethammer; E Mayer
Journal:  Bone Marrow Transplant       Date:  1998-04       Impact factor: 5.483

10.  Malignant neoplasms following bone marrow transplantation.

Authors:  S Bhatia; N K Ramsay; M Steinbuch; K E Dusenbery; R S Shapiro; D J Weisdorf; L L Robison; J S Miller; J P Neglia
Journal:  Blood       Date:  1996-05-01       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.